Lynkuet vs Veozah for Hot Flashes
Lynkuet vs Veozah: which non-hormonal hot flash pill is better, and what does each cost?
Reviewed by Taylor Anderson, RN
Aesthetic Registered Nurse
Taylor Anderson is an aesthetic registered nurse and a reviewer for Hot or Nothing.
Updated November 1, 2026
Quick answer
For hot flashes and night sweats, neither Lynkuet nor Veozah has been shown to work better than the other. Lynkuet is a bedtime capsule that also improved sleep but can cause drowsiness. Veozah needs regular liver blood tests and, with commercial insurance and Astellas's savings card, costs $0 the first month and as little as $30 a refill.
Want to feel turned on again? See which libido options fit you and what they cost.
See My PlanIn this guide
Key takeaways
- Lynkuet and Veozah both cut hot flashes a lot without hormones, and neither has been shown to beat the other, though the drop looked larger with Lynkuet.
- If night sweats are your main problem, ask about Lynkuet first, because you take it at bedtime and women slept better on it by week 12.
- Lynkuet can make you sleepy, so skip the morning drive until you know how it affects you, while Veozah carries the FDA's strongest warning for rare serious liver injury and needs liver blood tests through month 9.
- With commercial insurance and Astellas's Veozah Savings Card, Veozah costs $0 for the first month and as little as $30 a refill, while Bayer lists no Lynkuet price, so ask your pharmacy or insurer.
- Hormone therapy is still the most effective treatment for hot flashes, and Lynkuet and Veozah are for women who cannot take hormones or would rather not.
If hot flashes and night sweats are running your days and nights, Lynkuet (elinzanetant) and Veozah (fezolinetant) are both non-hormonal prescription medicines for moderate to severe menopause hot flashes, and no trial has compared them head to head. Lynkuet is taken at bedtime and also improved sleep in its trials. Veozah carries an FDA boxed warning for rare serious liver injury and needs regular liver blood tests. With commercial insurance and Astellas's savings card, Veozah costs $0 for the first month and as little as $30 a refill (Veozah savings, November 2026).
If you'd rather see whether a hormone plan fits instead, start with our hormones page.
Is Lynkuet or Veozah better for hot flashes?
Neither has been proven better, because no trial has put Lynkuet and Veozah head to head. The authors of a 2025 meta-analysis wrote that the two still need to be compared directly.
That meta-analysis is the closest look so far. It pooled 10 trials in 4,663 postmenopausal women, comparing each drug with placebo, not with each other. Both drugs cut hot flash frequency by 50% or more. The drop was larger for elinzanetant. Its average gap against placebo was -2.04, compared with -1.38 for fezolinetant.
The same review found that elinzanetant started working faster at higher doses and had a more favorable side-effect profile. Because it compared separate trials, treat this as a lean, not a verdict.
Our take: if night sweats are the main problem, ask about Lynkuet first. You take it at bedtime, and in both of its main trials it improved sleep disturbances compared with placebo at week 12. For more options, see our guide to treatments for perimenopause sleep problems.
How do Lynkuet and Veozah compare side by side?
| Lynkuet (elinzanetant) | Veozah (fezolinetant) | |
|---|---|---|
| FDA-approved use | The FDA label says it is "indicated for the treatment of moderate to severe vasomotor symptoms due to menopause." Vasomotor symptoms are hot flashes and night sweats. It was first approved in the US in 2025. It is not a hormone. | FDA approved for moderate to severe hot flashes due to menopause. Astellas describes it as "a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause." It is not a hormone. |
| How it works | It blocks two brain signals, called NK1 and NK3, involved in hot flashes. These signals act on the nerve cells in the brain's temperature control center that set off hot flashes (review). | It blocks one of those signals, NK3, which acts on the same temperature control center (review). |
| How you take it | Two 60 mg capsules (120 mg) once a day at bedtime, with or without food, swallowed whole. Avoid grapefruit and grapefruit juice (prescribing information). | Filled as a 30-day supply each month. |
| Main trial results | OASIS 1 and 2 enrolled 796 postmenopausal women with at least 50 moderate to severe hot flashes a week. They took Lynkuet or placebo for 12 weeks, then continued in a 14-week extension. They started with about 13 to 16 hot flashes a day. At week 12, women on Lynkuet had about 3 fewer moderate to severe hot flashes a day than women on placebo (-3.22 and -3.24) (FDA label). OASIS 3 followed 628 postmenopausal women aged 40 to 65 for 52 weeks. They started with about 6.7 hot flashes a day. At week 12, hot flashes fell by 5.4 a day on Lynkuet and by 3.5 on placebo. | One of its phase 3 trials, SKYLIGHT 1, was published in The Lancet in 2023. In the 2025 meta-analysis, fezolinetant's pooled drop in hot flash frequency against placebo was -1.38. |
| How fast it works | Hot flashes dropped as early as week 1 in OASIS 1 and 2. | The 2025 review compared separate trials and found elinzanetant took effect faster than fezolinetant at higher doses. |
| Liver warnings | The label asks for liver bloodwork before you start, plus follow-up checks. It says not to start if liver enzymes are at or above two times the upper limit of normal (prescribing information). OASIS 3 found no sign of liver harm. | It carries an FDA boxed warning for rare serious liver injury. FDA says the label "instructs patients to stop the medicine immediately and contact the health care professional who prescribed the medicine if signs and symptoms of liver injury occur." Astellas lists the liver blood tests: one before you start, then monthly for the first 3 months, then at month 6 and month 9. |
| Other label warnings | It can make you sleepy, and the label says not to drive until that wears off. In a driving simulator study of 64 healthy women, some drove worse 9 hours after their first bedtime dose. In August 2026 the label added a seizure warning and now tells women with a seizure history not to take it. It is not for use in pregnancy, and the label calls for contraception while you take it and for 2 weeks after you stop (prescribing information). | The boxed liver warning above. |
| Common side effects | The prescribing information warns that it can make you sleepy (see other label warnings above). | Stomach pain, diarrhea, trouble sleeping, back pain and hot flashes. |
| Who should not take it | Women who are pregnant, have liver problems or have a history of seizures. It also does not mix with strong medicines that act on CYP3A4, a liver enzyme that breaks down many drugs (prescribing information). | Women with cirrhosis, severe kidney problems or kidney failure, or who take certain medicines called CYP1A2 inhibitors. |
| Cost | Bayer's prescribing information sends you to lynkuet.com or 1-888-842-2937 for more information. Ask your pharmacy what your plan charges. | $0 for the first month and as little as $30 per monthly refill with commercial insurance and the Veozah Savings Card (Veozah savings, November 2026). |
Which one fits you, Lynkuet or Veozah?
Lynkuet suits you if your hot flashes hit hardest at night and you want a medicine that improved sleep in its trials. The trade-off is drowsiness. Take it at bedtime and skip the morning drive until you know how it affects you, as the label advises.
Veozah suits you if you have commercial insurance and want a predictable copay through the savings card (see the cost table below). The trade-offs are the boxed liver warning, blood tests through month 9, and trouble sleeping among its common side effects.
Your other medicines can make the choice for you. Lynkuet has to be avoided with strong CYP3A4 inhibitors, strong and moderate CYP3A4 inducers, and grapefruit juice (prescribing information). Veozah has to be avoided with CYP1A2 inhibitors. Bring your full medicine list to your clinical team.
How much does Veozah cost, and what about Lynkuet?
| Seller | Who it's for | What you pay | Conditions |
|---|---|---|---|
| Astellas, Veozah Savings Card (November 2026) | Commercial insurance | $0 for the first 30-day fill, then as little as $30 per monthly refill | The card covers up to $4,000 a year. It is not valid for Medicare, Medicaid or other government plans, and not valid for cash-paying patients. |
| Astellas Patient Assistance Program (November 2026) | No insurance | $0 if you meet its eligibility rules | Apply at VEOZAHaccess.com or call 1-866-239-1637. |
| Astellas, Veozah Support Solutions (November 2026) | Medicare Part D or Medicaid | Call to ask what help is available | 1-866-239-1637 |
| Bayer, Lynkuet (prescribing information) | Anyone | No price is listed in its prescribing information | Go to lynkuet.com or call 1-888-842-2937, and ask your pharmacy or insurer before you fill it. |
Astellas says 75% of Veozah prescriptions sent to insurers were approved nationwide from April 2025 to March 2026. Whoever prescribes it may need to submit a prior authorization first.
What if you can take hormones instead?
Menopausal hormone therapy is still widely recognized as the most effective treatment for hot flashes. Lynkuet and Veozah are for women who cannot take hormones or would rather not.
The breast cancer risk is small and specific. The same review estimates that five years of combined estrogen and progestin adds about 8 cases of invasive breast cancer per 10,000 women per year compared with placebo. It also notes that few women aged 50 to 55 have a reason they absolutely cannot take hormones.
We read 195 Reddit threads on menopause and hormone therapy from October 2025 to October 2026. 129 of 195 mentioned the patch and 107 of 195 mentioned progesterone, so most of the conversation included the patch.
Hot or Nothing is a third option for women open to hormones. Our hormones plans include bioidentical estrogen. You can compare the other routes in our guides to the best treatments for hot flashes and the best non-hormonal menopause treatments.
If you want cooler nights and sleep that lasts until morning, take the quiz and choose the hormones goal. Your clinical team will look at your symptoms and health history and tell you whether a hormones plan with bioidentical estrogen fits. You can read about the plans on our hormones page.
Ready to make a move?
Answer three questions to see the treatment options that fit your goals.
See My PlanFAQ
Does Lynkuet make you sleepy the next day?
Lynkuet can make you sleepy, and the label says not to drive until that wears off. In a driving simulator study of 64 healthy women, some drove worse 9 hours after their first bedtime dose, and a smaller share still did after 5 nights in a row. Take it at bedtime and skip the morning drive until you know how it affects you.
How fast does Lynkuet start working on hot flashes?
Lynkuet can start easing hot flashes in the first week. In its two main trials, hot flashes dropped as early as week 1. By week 12, women on Lynkuet had about 3 fewer moderate to severe hot flashes a day than women on placebo.
Does Medicare cover Veozah?
The Veozah Savings Card cannot be used with Medicare, Medicaid or other government plans, so the $0 first month and $30 refills do not apply if you have Medicare. If you have Medicare Part D, Astellas says to call Veozah Support Solutions at 1-866-239-1637 to ask what help is available. Whoever prescribes it may also need to get your plan's approval first.
Can you drink grapefruit juice on Lynkuet?
No. The Lynkuet label says to avoid grapefruit and grapefruit juice while you take it. The label lists grapefruit alongside strong CYP3A4 inhibitors, medicines that affect a liver enzyme that breaks down many drugs, which also have to be avoided. Bring your full medicine list to your clinical team.
Keep reading
Sources (5)
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials | Trials | JAMA | JAMA Network · jamanetwork.com · captured November 1, 2026
- Efficacy and safety of fezolinetant and elinzanetant for ... · pubmed.ncbi.nlm.nih.gov · captured November 1, 2026
- Review article Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis · sciencedirect.com · captured November 1, 2026
- Revised: 10/2025 · accessdata.fda.gov · captured November 1, 2026
- See full prescribing information for LYNKUET dosage modification due to drug interactions. (2.3) · labeling.bayerhealthcare.com · captured November 1, 2026
